Key Highlights
- UnitedHealth fell for a second straight day and led the Dow lower.
- CMS proposes scaling audit results across entire Medicare Advantage contracts.
- The rule has a legal history, and Oppenheimer expects legal challenges.
- Peers including Humana and Elevance Health fell harder still.
Day two of the selloff
UnitedHealth Group (NYSE:UNH) tumbled again on Wednesday, November 18, marking a second straight day of heavy selling. It was the worst stock on the Dow Jones Industrial Average and the main driver of the index's 561.25-point drop to 50,198.17.
What extrapolation means
The pressure stems from a proposed rule released by the Centers for Medicare and Medicaid Services on Monday, November 16. Called "Comprehensive Regulations to Uncover Suspicious Healthcare," or CRUSH, it targets Medicare Advantage risk adjustment data validation audits, usually shortened to RADV.
Under Medicare Advantage, the government pays private insurers a set amount to cover each enrollee, with higher payments for members whose medical records show more serious conditions. A RADV audit samples a plan's records to check whether the documented diagnoses support what was paid.
The key change is extrapolation. Instead of recovering money only for the specific records found to be unsupported in a sample, CMS would project the error rate from the sample to the entire contract. The proposal would apply that approach starting with payment year 2018.
CMS estimates the change at about $9 billion per payment year and about $90 billion in total savings over 10 years. CMS Administrator Dr. Mehmet Oz framed it as a way to "crush fraud, waste, and abuse." Those are CMS's figures and framing.
A rule with a legal history
The proposal is not final, and comments are due January 19, 2027. It revives a 2023 RADV rule that a federal judge in Texas vacated in September 2025 in a case brought by Humana (NYSE:HUM).
One analyst said, "The substantially larger collection estimate reflects broader auditing," adding that CMS "could choose to make adjustments in the final rule." Oppenheimer expects legal challenges.
Peers hit harder still
The selloff swept across managed care. Humana, which earned the bulk of its 2025 Revenue from Medicare Advantage, was the worst stock in the S&P 500. Elevance Health (NYSE:ELV), Centene (NYSE:CNC) and CVS Health (NYSE:CVS) all sank, and Cigna (NYSE:CI), Molina Healthcare (NYSE:MOH) and Oscar Health also fell.
The damage spilled into the wider sector. Health care was the S&P 500's second-worst group of the day, behind only energy. Drugmakers such as Merck (NYSE:MRK), Eli Lilly (NYSE:LLY), Johnson and Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) also moved lower, though no company-specific news was confirmed for them.
The broader indexes were mixed. The S&P 500 slipped 16.90 points to 7,323.63, its fifth straight loss and longest losing streak since June, while the Nasdaq Composite gained 101.50 points to 24,429.88.
Comment Period Becomes the Next Test for Insurers
The comment window is the next formal step, and the final rule could look different from the proposal. Investors will be watching how insurers and industry groups respond during that period, and whether any company quantifies its potential exposure. Oppenheimer has said it expects legal challenges, given the history of the 2023 rule, though how any challenge would play out cannot be predicted. For UnitedHealth specifically, management is expected to give its 2027 outlook before year-end, a release that could address the proposal's possible impact.






Please wait processing your request...